PuraPharm Corporation Limited filed its Monthly Return for the period ended 30 April 2026, confirming that no changes occurred in either its authorised or issued share capital during the month.

The authorised share capital stayed at 5.00 billion USD, representing 5.00 trillion ordinary shares with a par value of USD 0.001 each.

Issued share capital was unchanged at 535.90 million ordinary shares, and the company continued to hold zero treasury shares. The public float exceeded the Main Board’s 25 percent requirement.

Under the 2015 Share Option Scheme, 23.96 million options remained outstanding at month-end. No options were exercised, and no new shares were issued. If all outstanding options and the scheme’s remaining mandate were fully exercised, up to 31.79 million shares could be issued.

PuraPharm reported no warrants, convertibles, or other equity-linked instruments outstanding, and there were no repurchases, cancellations, or fund-raising activities during the month.